Poolbeg PharmaPOLBF -20.36% PB Ratio is 5.41 as of Jun. 24, 2026. The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, Poolbeg Pharma ranks worse than 74.45% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), Poolbeg Pharma's share price is $0.0919. Poolbeg Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was $0.02. Hence, Poolbeg Pharma's PB Ratio of today is 5.41.
The historical rank and industry rank for Poolbeg Pharma's PB Ratio or its related term are showing as below:
POLBF'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 6.33
Current: 6.33
During the past 5 years, Poolbeg Pharma's highest PB Ratio was 6.33. The lowest was 0.00. And the median was 0.00.
POLBF's PB Ratio is ranked worse than 74.45% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs POLBF: 6.33
During the past 12 months, Poolbeg Pharma's average Book Value Per Share Growth Rate was -36.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -31.30% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Poolbeg Pharma was -25.00% per year. The lowest was -31.30% per year. And the median was -28.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Poolbeg Pharma PB Ratio Related Terms
Poolbeg Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Poolbeg Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Poolbeg Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poolbeg Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Poolbeg Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Poolbeg Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Poolbeg Pharma (POLBF) has a PB Ratio of 5.41 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Poolbeg Pharma and its competitors. According to the industry distribution chart, Poolbeg Pharma ranks #918 out of 1233 companies in the Biotechnology industry, placing it in the top 74.5%.
Is Poolbeg Pharma's PB Ratio too high?
Poolbeg Pharma's current PB Ratio is 5.41. The Biotechnology industry median PB Ratio is 2.83. Poolbeg Pharma's value of 5.41 is 91.2% above this industry median. Based on the distribution chart, Poolbeg Pharma ranks #918 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint.
How does Poolbeg Pharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #918 out of 1233 companies for PB Ratio. This places Poolbeg Pharma in the lower half of its industry. The industry median PB Ratio is 2.83. Poolbeg Pharma's value of 5.41 is 91.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poolbeg Pharma's current PB Ratio of 5.41 is 91.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Poolbeg Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poolbeg Pharma's current PB Ratio is 5.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current PB Ratio of 5.41. The current PB Ratio is 5.41 and 91.2% above the Biotechnology industry median of 2.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current PB Ratio is 5.41 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POLBF has been successfully added to your 